Cordant Inc’s Haemonetics HAE Stock Holding History

Cordant Inc’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-15	Closed	-$1K	–	559
2022 Q1	$1K	Buy	+15	New	+$816	﹤0.01%	958

Other funds holding HAE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

LCP

LGT Capital Partners Pfaeffikon, Switzerland $1.88B AUM 20.37% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cordant Inc's HAE Position: Q2 2022 in Review

Cordant Inc sold out of Haemonetics (HAE) in Q2 2022, closing a stake of 15 shares — an estimated $1K sold.

Cordant Inc first reported a position in HAE in Q1 2022 and held it in 1 quarter. The position peaked at $1K in Q1 2022. 241 funds tracked by Wall St. Rank hold HAE as of Q2 2022.

Cordant Inc reported no remaining Haemonetics position as of Q2 2022 after selling out during the quarter.
Cordant Inc sold 15 Haemonetics shares in Q2 2022, an estimated $1K.
Cordant Inc first reported a position in Haemonetics in Q1 2022 and held it in 1 quarter.
Cordant Inc's Haemonetics position peaked at $1K in Q1 2022.
241 funds tracked by Wall St. Rank held Haemonetics as of Q2 2022.

Based on Cordant Inc's 13F filing for Q2 2022, filed 17 Aug 2022.